CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 25 enrolled / 25 target
Drug / intervention
Fedratinib Pilldrug
Likely dose
Fedratinib Pill 400 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05177211
NCT05177211Phase 2CompletedUpdate Overdue (0.5/mo)Completion was 14mo ago
CompareCT.gov

A Phase 2 Study of Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL)

H. Lee Moffitt Cancer Center and Research Institute·interventional·Posted Jan 4, 2022·Updated Jun 9, 2026

In Brief

A Phase 2 clinical trial evaluating Fedratinib Pill for Myeloproliferative Neoplasm and 2 related conditions. Completed, enrolled 25 participants across 3 sites.

Signals

Enrollment appears stalled

Detailed Summary

The purpose of the study is to evaluate the effectiveness, safety, and tolerability of a study drug called fedratinib in participants with myelodysplastic/myeloproliferative neoplasms (MDS/MPNs) and chronic neutrophilic leukemia (CNL).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMyeloproliferative Neoplasm, Chronic Neutrophilic Leukemia, MDS
CountriesUnited States
CollaboratorsBristol-Myers Squibb

Timeline

Phase 2CompletedFinished
20222023202420252026
First PostedJan 4, 2022
Enrollment StartMar 1, 2022
Primary CompletionApr 10, 2025
Study CompletionJan 9, 2026
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 4.5 years ago

Arms & Interventions

Treatment with Fedratinibexperimental

Participants will taken Fedratinib by mouth once a day every day of each 28 day cycle.

Drug: Fedratinib Pill

Interventions

Fedratinib Pilldrug

Participants will be given Fedratinib at a dose of 400 mg PO once daily (4-100 mg capsules). Fedratinib can be given at any time during the day, but patients are advised to take the dose at the same approximate time every day.